Skip to main content

Table 3 Correlation between the deposition of IgG subclasses along GBM and the clinical and pathological parameters of patients

From: The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease

  IgG1 IgG2 IgG3 IgG4
Positive (n=9) Negative (n=37) P Positive (n=22) Negative (n=24) P Strong/Linear (n=7) Weak/Segmental (n=39) P Positive (n=7) Negative (n=39) P
Age (years) 38.8±13.8 34.5±16.2 0.286 38.1±15.6 32.7±15.7 0.202 37.6±10.4 34.9±16.6 0.320 31.4±16.1 36±15.7 0.529
Gender (male/female) 5/4 27/10 0.308 15/7 17/7 0.845 5/2 27/12 0.907 6/1 26/13 0.313
Hydrocarbon exposure, n (%) 1/9 (11.1%) 2/35 (5.7%) 0.567 1/21 (4.8%) 2/23 (8.7%) 0.605 1/7 (14.3%) 2/37 (5.4%) 0.393 0/7 (0%) 3/37 (8.1%) 0.435
Prodromal infection, n (%) 6/9(66.7%) 13/37 (35.1%) 0.085 8/22 (36.4%) 11/24 (45.8%) 0.515 3/7 (42.9%) 16/39 (41.0%) 0.928 2/7 (28.6%) 17/39 (43.6%) 0.457
Smoking, n (%) 4/8 (50%) 20/37 (54.1%) 0.835 12/21 (57.1%) 12/24 (50%) 0.632 4/7 (57.1%) 20/38 (52.6%) 0.826 4/7 (57.1%) 20/8 (52.6%) 0.826
Gross hematuria, n (%) 2/9 (22.2%) 13/37 (35.1%) 0.459 9/22 (40.9%) 6/24 25%) 0.250 0/7 (0%) 15/39 (38.5%) 0.046 3/7 (42.9%) 12/39 (30.8%) 0.530
Nephrotic syndrome, n (%) 3/5(60.0%) 16/26 (61.5%) 0.948 8/14 (57.1%) 11/17 (64.7%) 0.667 4/6 (66.7%) 15/25 (60%) 0.763 4/5 (80%) 15/26(57.7%) 0.348
Hemoglobin (g/L) 94±28.5 83.5±25.2 0.493 90.6±24.2 80.9±27.6 0.146 105.1±25.8 82.0±24.9 0.038 84.3±29.7 85.9±25.9 0.818
Oliguria/anuria, n (%) 3/9(33.3%) 11/37 (29.7%) 0.833 7/22 (31.8%) 7/24 (29.2%) 0.845 0/7 (0%) 14/39 (35.9%) 0.057 2/7 (28.6%) 12/39 (30.8%) 0.907
Serum creatinine at presentation (μmol/L) 503.8±341.9 783.2±371.0 0.031 674.9±373.7 777.8±384.6 0.350 445.4±333.0 779.4±367.4 0.028 825±532.6 711.2±350.8 0.490
Anti-GBM antibodies (U/mL) 56.1±34.9 69.7±40.8 0.359 90.6±24.2 80.9±27.6 0.452 39.8±42.9 70±38.7 0.060 64.5±59.5 67.4±36.3 0.566
ANCA, n (%) 2/9 (22.2%) 7/37 (18.9%) 0.823 4/18 (22.2%) 5/24 (20.8%) 0.821 0/9 (0%) 9/39 (23.1%) 0.156 2/7 (28.6%) 7/39 (17.9%) 0.514
Percentage of total crescents (%) 60.6±44.3 832±23.6 0.397 76.4±30.1 81.0±29.7 0.587 54.7±47.0 83.1±23.8 0.183 68.9±38.7 80.5±28 0.719
Cellular crescents (%) 43.3±36.1 64.5±32.3 0.086 65.3±34.0 55.8±33.6 0.285 39.6±34.8 64.0±32.6 0.093 58.9±38.6 60.6±33.4 1
Fibrotic crescents (%) 34.5±32.9 32.8±30.9 0.892 25.6±27.9 40.1±32.5 0.113 31.8±30.8 33.4±31.4 0.858 41.1±38.6 31.7±29.8 0.590
C3 deposits (median) 2 1 1.000 0 1 0.627 2 1 0.131 2 1 0.131
Ultrastructrual lesions 2 2 0.438 2 2 0.727 2 2 0.438 2 2 0.438
Renal survival (1 year), n (%) 3/9 (33.3%) 7/37 (18.9%) 0.347 5/22 (22.7%) 5/24 (20.8%) 0.876 4/7 (57.1%) 7/39 (17.9%) 0.141 1/7 (14.3%) 9/39 (23.1%) 0.604
Patient survival (1 year), n (%) 6/9 (66.7%) 30/37 (81.1%) 0.347 17/22 (77.3%) 19/24 (79.2%) 0.876 7/7 (100%) 29/39 (74.4%) 0.130 4/7 (57.1%) 32/39 (82.1%) 0.141
  1. GBM: glomerular basement membrane; ANCA: anti-neutrophil cytoplasmic antibody.